Pershing and Valeant Pharmaceuticals deal for Allergan approved

Noam Stiekema

The US court approved deal of Pershing Square Capital and Valeant Pharmaceuticals for Allergan. Earlier in October manufacturer of Botox complained to the court against the 9.7% share of Pershing Square Capital, which is claimed to be acquired violating the rules of insider trading. Pershing Square Capital and Valeant Pharmaceuticals convened meeting of shareholders in […]

Allergan

AllerganThe US court approved deal of Pershing Square Capital and Valeant Pharmaceuticals for Allergan. Earlier in October manufacturer of Botox complained to the court against the 9.7% share of Pershing Square Capital, which is claimed to be acquired violating the rules of insider trading. Pershing Square Capital and Valeant Pharmaceuticals convened meeting of shareholders in mid-December, at which shareholders will vote on the removal of part of the management under the leadership of Executive Director David Assumption. The both companies plan to appoint a more manageable guide. They have already won the support of 35% of shareholders for the meeting, but will need at least another 15% to win the vote against the current management.

In October the both companies proposed new offer – 4.50 billion USD higher than the previous one, which increases the assessment Allergan to 56 billion USD. If ingestion occurs at this price, it will be the largest corporate deal of the year and will surpass another transaction in the industry – the purchase of AbbVies by Shire for the price of 54 billion USD, which is not yet completed.

A possible merger of Valeant with Allergan would help the Canadian company, which in 2010 is located in the active period of acquisitions to become one of the top five players in terms of market capitalization in the sector by 2016, as are the ambitions stated of its chief executive Michael Pearson. This step represents the next movement in the pharmaceutical industry, which began in 2011 and reached its peak in April with the measures taken by companies such as Pfizer, GlaxoSmithKline (GSK) and Novartis. According to the agency in the last few months in the sector took place mergers and acquisitions worth 141 billion USD.

Meanwhile, just days after the “unwanted investor” Valeant Pharmaceuticals International and investor William Ackman said it may raise its bid for Allergan, a new candidate intends to submit a proposal for the acquisition of the maker of Botox. It is assumed that this is Actavis. Rumors that Actavis sought after experience in the summer to make another attempt to acquire, float in the space of about four weeks. The management obviously wants to avoid at all costs ingestion of Canadians. What extent this is economically justified, is not yet clear. Many analysts believe a merger with Valeant strategic correctly. But in case not, analysts and investors have the last word. And some of them seem to welcome a possible merger with Actavis. It is expected that the acquisition or merger with Allergan to be good as the shares of the maker of Botox and the winner of the securities in dispute it. So for those who have in their portfolio share of Actavis, rather than Valeant, it is better to support a slightly bad deal economically. Although small shareholders Allergan can not greatly influence the decision they get serious comfort. Who has invested in the company last year, has doubled their money and shares yesterday marked a new peak to 193.55 dollars a share. And that’s not all. Valeant has said it may offer 200 USD per share. According to various speculation of a merger between Allergan and Actavis transaction value would still be over 200 USD per share.

Read this next

Digital Assets

Top exec at BitMEX pled guilty US Bank Act violations, pays $150K fine

BitMEX’s head of business development, Gregory Dwyer pled guilty to violating the US Bank Secrecy Act (BSA) and allowing customers to use the platform to circumvent the federal anti-money laundering rules.

Retail FX

CySEC slaps €150,000 fine on FXBFI, operator of 101investing brand

The Cyprus Securities and Exchange Commission (CySEC) today announced that it has reached a settlement with FXBFI Broker Financial Invest Ltd, trading as 101investing, ordering the firm to pay €150,000 for violating the Investment Services and Activities and Regulated Markets Law.

Retail FX

X Open Hub expands multi-asset offering with new cryptocurrencies and indices

X Open Hub, a multi-asset liquidity provider, announced today that it has extended its offering with inclusion of 30 new cryptocurrencies and two emerging market indices.

Retail FX

Interactive Brokers now offers 24/7 access to crypto trading

Interactive Brokers Group, Inc. (NASDAQ: IBKR) has widened access to cryptocurrency trading for its clients. Specifically, the discount broker extended trading hours for its cryptocurrency products to be traded 24/7, including on the weekends.

Inside View

Natural Language Generation for Multi-Language Social Media Strategies 

Natural Language Generation (NLG) is a crucial growth area in the digital landscape, with the unique potential to be used across multiple industries.

Market News, Technology

The B2Core Android App is Now Available For Download

The first version of the B2Core Android app is available for download, and it has many beneficial features for users.

Digital Assets

XBO taps custodian Fireblocks ahead of crypto exchange’s launch

XBO.com has integrated with digital asset and crypto technology platform Fireblocks ahead of the crypto exchange’s upcoming launch.

Industry News

Appital raises another £1.7m after integrating with FactSet, FlexTrade, and TS Imagine

“Appital has a proven track record in securing partnerships with major EMS providers, executing brokers and a trading venue to address the lack of efficiency and control over existing bookbuilding and deal distribution processes.”

Digital Assets

Tim Draper backs crypto-focused asset manager OSD in seed round

“The Old Street Digital team is well-positioned to provide access to a range of research-backed, crypto-based investment funds, and we at Draper Associates are excited to support them.”

<